Latest Articles and Analysis

New Phase 3 data show a single-tablet regimen of bictegravir/lenacapavir could finally bring one-pill simplicity to long-term HIV survivors locked into complex regimens by decades of drug resistance. The science is closing the treatment gap. Will our policy systems do the same?

Pharmaceutical industry engagement of patient advocates requires transparency about funding, conflicts of interest, and advocacy independence.

Antibiotic-resistant bacteria threaten basic medical procedures while drug development incentives prove inadequate for innovation.

Analyzes Biden health policy priorities including drug pricing reform and Medicare expansion.

Calls for restoring Obama-era guidance defining 340B patient protections and enforcement mechanisms.

Merck-Gilead partnership on long-acting injectables Islatravir and Lenacapavir for HIV treatment.